A New Hypromellose Excipient for Direct-Compression, Controlled-Release Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A New Hypromellose Excipient for Direct-Compression, Controlled-Release Applications
The authors examine the use of a hypromellose-based product as an excipient in a controlled release formulation using direct-compression tableting.


Pharmaceutical Technology



Authors
Direct compression (DC) is becoming a preferred manufacturing method for tablets. This process is less complicated than dry- or wet-granulation processes and therefore offers shorter product-development timelines and reduced cost to manufacture through the elimination of granulation unit operations. In addition, DC can be used for heat- and/or moisture-sensitive active pharmaceutical ingredients (APIs) because it has a low heat history and does not require water during processing. Excipients used in DC processing, however, must have a combination of properties, including good flow, compressibility, minimal segregation tendency, and good physical and chemical compatibility—a combination not usually associated with controlled-release (CR) excipients. A new family of hypromellose (HPMC) products (Methocel cellulose ethers, Dow Chemical, Midland, MI) was developed that combines these properties with the ability to provide controlled-drug release.

HPMC products are widely used rate-controlling polymers in oral controlled-release drug-delivery applications. These excipients offer flexibility in formulation and function for preparation of oral solid-dosage forms. However, their application in DC tableting processes is limited in some cases and complicated in others because of their poor powder flow properties. Recent product development efforts have improved powder flow while maintaining suitable compressibility and CR performance and minimizing segregation.

DC and the use of CR excipients


Figure 1
DC is a tableting process in which a dry blend of ingredients is placed into a tablet hopper and compressed into tablets. It is a much simpler process than wet or dry granulation, eliminating several unit operations and resulting in a more straightforward manufacturing system (see Figure 1). This results in lower manufacturing costs and shorter development times for new formulations. DC has the added advantage of being less harsh on heat- and moisture-sensitive APIs.

The main parameters for an ideal DC excipient are flowability, compressibility, minimal tendency to segregate, and physical and chemical compatibility with APIs and other ingredients. Reliable flow of pharmaceutical mixtures out of tablet-press hoppers is particularly important for problem-free tablet-press operation and consistent tablet properties. Failure to ensure reliable flow can result in both considerable manual interventions for the tablet-press hopper and poor tablet physical properties, such as high tablet-to-tablet weight variability and tablet hardness.

Because HPMC has generally poor flow properties and is often present in formulations at high levels (up to 30%), it can have a serious effect on formulation flow in a DC process. As a result, preparing CR formulations with a DC process can be difficult, usually requiring compromises such as flow enhancers or slower production rates. Typically, CR formulations are processed using wet granulation to achieve adequate mixing and improved flow. If the flow properties of HPMC could be improved, the less costly DC process could be used.

Influence of material properties and environmental factors on powder flow


Figure 2
Powder flow can be a difficult property to quantify because it is influenced by so many factors. Material properties such as particle size and distribution, bulk density, particle shape, moisture content, and cohesiveness all have a role in determining powder flow (1). In addition, environmental factors such as humidity, particle-to-wall interactions, bin and hopper design and dimensions, consolidation time, and load affect powder processing. Measuring powder flow with conventional bench-scale tests can be deceptive because small-scale processes primarily show the effects of particle-to-particle cohesion. If two products have the same chemistry, the particle-to-particle cohesion will be similar. At a larger scale, however, more relevant to production processes, there is an increased influence of gas permeability of the bulk solid. If the gas permeability of the bulk solid is low, the flowing solid is unable to dilate in the conical section of the hopper, a phenomenon referred to as "limiting flow rate."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here